merck glp-1 agonist Design and discovery of a highly potent ultralong-acting and glucagon co-agonist for attenuating renal fibrosis GLP-1 Medications for Weight Loss:

Originally developed for diabetes, GLP-1RAs have become a lifeline for millions seeking effective, sustainable weight loss solutions.

subdistribution HR [SHR] 0.63 [95% CI 0.41, 0.96]), primarily due to lower rates of amputation (1.29 events per 1000 person-years for GLP1RAs vs 2.4 events per 1000 person-years for DPP4is

Our board-certified physicians provide personalized care from consultation to follow-up

Anyone considering changing or stopping a prescribed medication should speak with a qualified healthcare professional first

Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial